Acute Porphyria Drug Database

J07BB03 - Influenza, Live Attenuated
Propably not porphyrinogenic
PNP

Important Information
Risk for gastrointestinal adverse events in the form decreased appetite motivates vigilance against insufficient intake of food, especially of carbohydrate.
Side effects
Decreased appetite is reported as a very common side effect and may potentially be porphyrinogenic if leading to a decrease in carbohydrate intake.
Rationale
Based on the pharmacokineticsof the influeza vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Risk for gastrointestinal adverse events in the form decreased appetite motivates vigilance against insufficient intake of food, especially of carbohydrate.
Therapeutic characteristics
Prophylaxis of influenza in children and adolescents between 2-18 years. The live attenuated influenza vaccine is for nasal administration and is given as one divided dose in both nostrils.
Metabolism and pharmacokinetics
The influenza vaccine is not metabolized by the Cytochrome P450 system.

References

  1. Government bodies
  2. Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015). #1857
  3. Summary of Product Characteristics
  4. The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Fluenz. (Last edition: 29.07. 2016). #3202

Similar drugs
Explore alternative drugs in similar therapeutic classes J07B / J07BB or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙